Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Emory University
NRG Oncology
NRG Oncology
City of Hope Medical Center
NRG Oncology
NRG Oncology
M.D. Anderson Cancer Center
Mayo Clinic
Assistance Publique - Hôpitaux de Paris
Mayo Clinic
Roswell Park Cancer Institute
Stanford University
University of Washington
Fred Hutchinson Cancer Center
Mayo Clinic
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Thomas Jefferson University
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Ohio State University Comprehensive Cancer Center
Emory University
Thomas Jefferson University
University of Washington
University of Rochester
Jonsson Comprehensive Cancer Center
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
University of Washington
City of Hope Medical Center
University of Washington
City of Hope Medical Center
Jonsson Comprehensive Cancer Center
University of Michigan Rogel Cancer Center
Northwestern University
Barbara Ann Karmanos Cancer Institute
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
NRG Oncology
Vanderbilt-Ingram Cancer Center
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
IRCCS San Raffaele
City of Hope Medical Center
Mayo Clinic
University of Utah